Overview

Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this clinical study are threefold: 1. To compare the benefits in cancer control and survival obtained from adding induction-concurrent chemotherapy to radiation with those from adding concurrent-adjuvant chemotherapy to radiation. 2. To test whether replacing fluorouracil with Xeloda in combining with cisplatin in the chemotherapy plan will maintain or improve further the chemotherapy benefits while reducing the duration of hospital stay. 3. To see if accelerated fractionation radiotherapy can improve the outcome of patients as compared with conventional fractionation radiotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Hong Kong Nasopharyngeal Cancer Study Group Limited
Collaborators:
hong Kong Cancer Fund
The Hong Kong Anti-Cancer Society
Treatments:
Capecitabine
Fluorouracil